GET INVOLVED
Linkedin X-twitter
Back
  • 24 November 2025

Respiratory adherence tool to enhance inhaled therapy and provides adherence and disease management

Keywords: Digital Health
Logo DHU white
erc connect approved
Owner
Sabine Häussermann, PhD, VisionHealth GmbH
VisionHealth GmbH was founded in Munich, Germany, in 2017, and its US subsidiary in Boston, MA, in 2024. The company has been continuously active since 2017. Kata has been available in the Apple and Google Play Stores since 2019 and is used by over 2,000 patients in Germany and the USA. The solution has been evaluated in four clinical trials involving 250 patients, with additional real-world pilots scheduled at the University of Michigan and Columbia University starting in early 2026. VisionHealth and Kata comply with ISO 27001 (information security management) and ISO 13485 (medical device quality management systems).

Link

Type
Digital solution and service (e.g. application/digital health portal/platform/AI based system/etc.)
we are developing and distributing AI based algorithms to coach daily inhalation. the algorithms run on any smartphone and are embedded in an App called Kata.
Short description

KATA® is the first AI-powered, FDA-cleared, CE-marked, medical device application that monitors and coaches correct inhaler use in real time, for any inhaler, on all smartphones, with no extra hardware.

It even works offline or without data plan, critical in underserved communities.

Kata is clinically proven – evaluated in 7 clinical trials and pilots, KATA reduced critical inhaler errors by 85-100%, outperforming most standard inhaler training and adherence programs.

Kata is currently available for asthma and COPD patients in Europe, and for asthma patients in the US. While it can in principle support any inhaled therapy, current deployments focus on airway diseases.

Access is presently arranged through our partner pilots in Germany and the US, or via our website’s contact form. We are expanding partner collaborations for clinical trials and real-world projects, with the goal of achieving reimbursement pathways for Kata.

Kata is well adopted by users, it is already in the hands of 2 500+ patients. VisionHealth has active Pharma and Medtech partnerships.

Evidence
Impact on health outcomes, Economic value to health and care systems, Contribution to citizen empowerment
Maturity
The practice/case/tool is “on the market” and integrated in routine use. There is proven market impact in terms of job creation/spin-off creation or other company growth
The application is availiable in Europe, and distributed in Germany and USA via partners.
Countries
Germany
Other (please specify in free text box below)
USA
Geographical scope
European
In Europe, we started in Germany, but would like to roll out to other countries, resources permitting.
Language(s)
German, English, Spanish
Comment
Kata is used by more than 2500 patients. Additionally to our Medtech partnership in the US, we will be starting pilots at Columbia University and University of MIchigan serving Medicaid patients. A demo version of Kata is available upon request. Currently, interested users who contact us receive access for 90 days.
Submitted in other database or repository of digital health resources that is publicly available
no

Additional information

Relations
to clinicians / care practitioners
Health data analytics (Artificial Intelligence/algorithm development and calibration/machine learning/risk stratification tools/etc.)
Care pathway tracking and adherence
to patients / citizens
Remote monitoring apps/health outcomes tracking
Primary target patient group (age)
Youth and young adults (15-24), Adults (25-64), Older adults (65+)
Addressed prevention area(s)
Education
educating on effective use of inhaler technique
Use case and care pathway positioning
Treatment, Disease monitoring, treatment compliance, self-management
Ready to be transferred to
The practice has been transferred in other locations, regions or national scale in the same country.
Plans for cross-border implementation
Are considered and will be developed in the near future
Back